

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/Capplus enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/Capplus and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/Capplus
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/Capplus(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/Capplus enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/Capplus fields enhanced with simultaneous left and right truncation
NEWS	20	SEP 25	CA(SM)/Capplus(SM) display of CA Lexicon enhanced
NEWS	21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:22:48 ON 29 SEP 2006

=> file medline, biosis, biotechds, wpids, dgene, embase, hcaplus, uspatful
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 17:23:27 ON 29 SEP 2006

FILE 'BIOSIS' ENTERED AT 17:23:27 ON 29 SEP 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 17:23:27 ON 29 SEP 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPIDS' ENTERED AT 17:23:27 ON 29 SEP 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'DGENE' ENTERED AT 17:23:27 ON 29 SEP 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 17:23:27 ON 29 SEP 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 17:23:27 ON 29 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:23:27 ON 29 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s solution formulation and (stable)
L1 1047 SOLUTION FORMULATION AND (STABLE)

=> s l1 and (GLP)
L2 39 L1 AND (GLP)

=> s l2 and (pH 8.2)
4 FILES SEARCHED...
L3 0 L2 AND (PH 8.2)

=> s l2 and (pH 8.8)
L4 0 L2 AND (PH 8.8)

=> s l2 and (mutation)
L5 8 L2 AND (MUTATION)

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 8 USPATFULL on STN

TI 2,4-Pyrimidinediamine compounds and their uses

AB The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:160006 USPATFULL
TITLE: 2,4-Pyrimidinediamine compounds and their uses
INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES
Argade, Ankush, Foster City, CA, UNITED STATES
Payan, Donald, Hillsborough, CA, UNITED STATES
Molineaux, Susan, San Mateo, CA, UNITED STATES
Holland, Sacha J., San Francisco, CA, UNITED STATES
Clough, Jeffrey, Redwood City, CA, UNITED STATES
Keim, Holger, Menlo Park, CA, UNITED STATES
Bhamidipati, Somasekhar, Foster City, CA, UNITED STATES
Sylvain, Catherine, Burlingame, CA, UNITED STATES
Li, Hui, Milbrae, CA, UNITED STATES
Rossi, Alexander B., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006135543	A1	20060622
APPLICATION INFO.:	US 2005-299207	A1	20051208 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-858343, filed on 1 Jun 2004, PENDING Continuation of Ser. No. US 2003-355543, filed on 31 Jan 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353333P	20020201 (60)
	US 2002-353267P	20020201 (60)
	US 2002-399673P	20020729 (60)
	US 2002-434277P	20021217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DECHERT LLP, P.O. BOX 10004, PALO ALTO, CA, 94303, US	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	7470	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 8 USPATFULL on STN
TI 2,4-pyrimidinediamine compounds and their uses
AB The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:68070 USPATFULL
TITLE: 2,4-pyrimidinediamine compounds and their uses
INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES
Argade, Ankush, Foster City, CA, UNITED STATES
Payan, Donald, Hillsborough, CA, UNITED STATES
Molineaux, Susan, San Mateo, CA, UNITED STATES
Holland, Sacha J., San Francisco, CA, UNITED STATES
Clough, Jeffrey, Redwood City, CA, UNITED STATES
Keim, Holger, Menlo Park, CA, UNITED STATES
Bhamidipati, Somasekhar, Foster City, CA, UNITED STATES
Sylvain, Catherine, Burlingame, CA, UNITED STATES
Li, Hui, Millbrae, CA, UNITED STATES

Rossi, Alexander B., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006058292	A1	20060316
APPLICATION INFO.:	US 2005-149418	A1	20050608 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-355543, filed on 31 Jan 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353333P	20020201 (60)
	US 2002-353267P	20020201 (60)
	US 2002-399673P	20020729 (60)
	US 2002-434277P	20021217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DECHERT LLP, P.O. BOX 10004, PALO ALTO, CA, 94303, US	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	9639	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L5 ANSWER 3 OF 8 USPATFULL on STN

TI Pharmaceutical materials and methods for their preparation and use

AB Pharmaceutical compositions comprising crystals of a pharmaceutically-acceptable crystal lattice component, and an active pharmaceutical ingredient different from and included within the crystal lattice component in a growth-sector specific orientation. The crystals are prepared using components and methods which yield crystals having suitable purity and efficacy for use in administering the active pharmaceutical ingredients to a patient. The crystals are typically combined with adjuvants such as excipients, diluents or carriers, and are preferably formulated into tablets, capsules, suspensions, and other conventional forms containing predetermined amounts of the pharmaceuticals. Also provided are methods for preparing the crystals, and methods for storing and administering the active pharmaceutical ingredient either included within the crystals or upon reconstitution of the crystals to a solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:43270 USPATFULL

TITLE: Pharmaceutical materials and methods for their preparation and use

INVENTOR(S): Chmielewski, Jean A., Lafayette, IN, UNITED STATES
Kahr, Bart E., Seattle, WA, UNITED STATES
Lewis, Jerry, Carmel, IN, UNITED STATES

PATENT ASSIGNEE(S): Purdue Research Foundation, West Lafayette, IN, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7001892	B1	20060221
	WO 2000076480		20001221
APPLICATION INFO.:	US 2001-18043		20000612 (10)
	WO 2000-US16140		20000612
			20020521 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-138912P	19990611 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Maier, Leigh C.
LEGAL REPRESENTATIVE: Woodard, Emhardt, Moriarty, McNett & Henry LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 3165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 8 USPATFULL on STN
TI 2,4-Pyrimidinediamine compounds and their uses
AB The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:41264 USPATFULL
TITLE: 2,4-Pyrimidinediamine compounds and their uses
INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES
Argade, Ankush, Foster City, CA, UNITED STATES
Payan, Donald, Hillsborough, CA, UNITED STATES
Molineaux, Susan, San Mateo, CA, UNITED STATES
Holland, Sacha J., San Francisco, CA, UNITED STATES
Clough, Jeffrey, Redwood City, CA, UNITED STATES
Keim, Holger, Menlo Park, CA, UNITED STATES
Bhamidipati, Somasekhar, Foster City, CA, UNITED STATES
Sylvain, Catherine, Burlingame, CA, UNITED STATES
Li, Hui, Millbrae, CA, UNITED STATES
Rossi, Alexander B., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006035916	A1	20060216
APPLICATION INFO.:	US 2005-148746	A1	20050608 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-355543, filed on 31 Jan 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353333P	20020201 (60)
	US 2002-353267P	20020201 (60)
	US 2002-399673P	20020729 (60)
	US 2002-434277P	20021217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DECHERT LLP, P.O. BOX 10004, PALO ALTO, CA, 94303, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	7224	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 8 USPATFULL on STN
TI 2,4-Pyrimidinediamine compounds and their uses
AB The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of

contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:28576 USPATFULL
TITLE: 2,4-Pyrimidinediamine compounds and their uses
INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES
Argade, Ankush, Foster City, CA, UNITED STATES
Payan, Donald, Hillsborough, CA, UNITED STATES
Molineaux, Susan, San Mateo, CA, UNITED STATES
Holland, Sacha J., San Francisco, CA, UNITED STATES
Clough, Jeffrey, Redwood City, CA, UNITED STATES
Keim, Holger, Menlo Park, CA, UNITED STATES
Bhamidipati, Somasekhar, Foster City, CA, UNITED STATES
Sylvain, Catherine, Burlingame, CA, UNITED STATES
Li, Hui, Millbrae, CA, UNITED STATES
Rossi, Alexander B., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006025410	A1	20060202
APPLICATION INFO.:	US 2005-149105	A1	20050608 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-355543, filed on 31 Jan 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353333P	20020201 (60)
	US 2002-353267P	20020201 (60)
	US 2002-399673P	20020729 (60)
	US 2002-434277P	20021217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DECHERT LLP, P.O. BOX 10004, PALO ALTO, CA, 94303, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	7232	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 8 USPATFULL on STN
TI 2,4-Pyrimidinediamine compounds and their uses
AB The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:241225 USPATFULL
TITLE: 2,4-Pyrimidinediamine compounds and their uses
INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES
Argade, Ankush, Foster City, CA, UNITED STATES
Payan, Donald, Hillsborough, CA, UNITED STATES
Molineaux, Susan, San Mateo, CA, UNITED STATES
Holland, Sacha J., San Francisco, CA, UNITED STATES
Clough, Jeffrey, Redwood City, CA, UNITED STATES
Keim, Holger, Menlo Park, CA, UNITED STATES

Bhamidipati, Somasekhar, Foster City, CA, UNITED STATES
Sylvain, Catherine, Burlingame, CA, UNITED STATES
Li, Hui, Millbrae, CA, UNITED STATES
Rossi, Alexander B., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005209230	A1	20050922
APPLICATION INFO.:	US 2004-911684	A1	20040803 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-355543, filed on 31 Jan 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353333P	20020201 (60)
	US 2002-353267P	20020201 (60)
	US 2002-399673P	20020729 (60)
	US 2002-434277P	20021217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111, US	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	21979	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L5 ANSWER 7 OF 8 USPATFULL on STN
TI 2, 4-pyrimidinediamine compounds and their uses
AB The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:44509 USPATFULL
TITLE: 2, 4-pyrimidinediamine compounds and their uses
INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES
Argade, Ankush, Foster City, CA, UNITED STATES
Payan, Donald, Hillsborough, CA, UNITED STATES
Molineaux, Susan, San Mateo, CA, UNITED STATES
Holland, Sacha J., San Francisco, CA, UNITED STATES
Clough, Jeffrey, Redwood City, CA, UNITED STATES
Keim, Holger, Menlo Park, CA, UNITED STATES
Bhamidipati, Somasekhar, Foster City, CA, UNITED STATES
Sylvain, Catherine, Burlingame, CA, UNITED STATES
Li, Hui, Millbrae, CA, UNITED STATES
Rossi, Alexander B., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005038243	A1	20050217
	US 7060827	B2	20060613
APPLICATION INFO.:	US 2004-858343	A1	20040601 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-355543, filed on 31 Jan 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353333P	20020201 (60)
	US 2002-353267P	20020201 (60)
	US 2002-399673P	20020729 (60)
	US 2002-434277P	20021217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Scott D. Rothenberger, Esq., DORSEY & WHITNEY LLP, Intellectual Property Department, 50 South Sixth Street, Suite 1500, Minneapolis, MN, 55402-1498	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	22089	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L5 ANSWER 8 OF 8 USPATFULL on STN

TI 2,4-Pyrimidinediamine compounds and their uses

AB The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:39360 USPATFULL

TITLE: 2,4-Pyrimidinediamine compounds and their uses

INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES
Argade, Ankush, Foster City, CA, UNITED STATES
Payan, Donald, Hillsborough, CA, UNITED STATES
Molineaux, Susan, San Mateo, CA, UNITED STATES
Holland, Sasha J., San Francisco, CA, UNITED STATES
Clough, Jeffrey, Redwood City, CA, UNITED STATES
Keim, Holger, Menlo Park, CA, UNITED STATES
Bhamidipati, Somasekhar, Foster City, CA, UNITED STATES
Sylvain, Catherine, Burlingame, CA, UNITED STATES
Li, Hui, Millbrae, CA, UNITED STATES
Rossi, Alexander B., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004029902	A1	20040212
APPLICATION INFO.:	US 2003-355543	A1	20030131 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353333P	20020201 (60)
	US 2002-353267P	20020201 (60)
	US 2002-399673P	20020729 (60)
	US 2002-434277P	20021217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111	
NUMBER OF CLAIMS:	71	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	22587	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e brader/au

E1	1	BRADENSTEIN M/AU
E2	1	BRADENSTEIN MECHTILDE/AU
E3	0	--> BRADER/AU
E4	12	BRADER A/AU
E5	2	BRADER A B/AU
E6	4	BRADER A C/AU
E7	3	BRADER A H/AU
E8	1	BRADER AAFKE/AU
E9	1	BRADER ALAN H/AU
E10	4	BRADER ALLEN C/AU
E11	2	BRADER ANTON/AU
E12	2	BRADER B/AU

=> s e4

L6 12 "BRADER A"/AU

=> s l6 and l2

L7 0 L6 AND L2

=> s e5

L8 2 "BRADER A B"/AU

=> s e6

L9 4 "BRADER A C"/AU

=> s l8 and l2

L10 0 L8 AND L2

=> s l9 and l2

L11 0 L9 AND L2

=> d his

(FILE 'HOME' ENTERED AT 17:22:48 ON 29 SEP 2006)

FILE 'MEDLINE, BIOSIS, BIOTECHDS, WPIDS, DGENE, EMBASE, HCAPLUS, USPATFULL' ENTERED AT 17:23:27 ON 29 SEP 2006

L1	1047	S SOLUTION FORMULATION AND (STABLE)
L2	39	S L1 AND (GLP)
L3	0	S L2 AND (PH 8.2)
L4	0	S L2 AND (PH 8.8)
L5	8	S L2 AND (MUTATION)
		E BRADER/AU
L6	12	S E4
L7	0	S L6 AND L2
L8	2	S E5
L9	4	S E6
L10	0	S L8 AND L2
L11	0	S L9 AND L2

=> s (GLP) and (tonicity modifier) and (perservative)

L12 0 (GLP) AND (TONICITY MODIFIER) AND (PERSERVATIVE)

=> s (preservative) and (GLP) and (tonicity modifier)

L13 50 (PRESERVATIVE) AND (GLP) AND (TONICITY MODIFIER)

=> d his

(FILE 'HOME' ENTERED AT 17:22:48 ON 29 SEP 2006)

FILE 'MEDLINE, BIOSIS, BIOTECHDS, WPIDS, DGENE, EMBASE, HCAPLUS,
USPATFULL' ENTERED AT 17:23:27 ON 29 SEP 2006

L1 1047 S SOLUTION FORMULATION AND (STABLE)
L2 39 S L1 AND (GLP)
L3 0 S L2 AND (PH 8.2)
L4 0 S L2 AND (PH 8.8)
L5 8 S L2 AND (MUTATION)
E BRADER/AU
L6 12 S E4
L7 0 S L6 AND L2
L8 2 S E5
L9 4 S E6
L10 0 S L8 AND L2
L11 0 S L9 AND L2
L12 0 S (GLP) AND (TONICITY MODIFIER) AND (PERSERVATIVE)
L13 50 S (PRESERVATIVE) AND (GLP) AND (TONICITY MODIFIER)

=> s l13 and l2

L14 0 L13 AND L2

Refine Search

Search Results -

Terms	Documents
L8 and L3	0

Database:

US Pre-Grant Publication Full-Text Database

US Patents Full-Text Database

US OCR Full-Text Database

EPO Abstracts Database

JPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Search:

L9

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Friday, September 29, 2006 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR

L9 L8 and l3 0 L9

L8 L7 and (preservative) 33 L8

L7 L6 and (tonicity modifier or glycerin) 67 L7

L6 l4 and mutation 301 L6

L5 L4 and l3 0 L5

L4 l1 1130 L4

L3 L2 72 L3

DB=USPT; PLUR=YES; OP=OR

L2 brader.in. 72 L2

L1 GLP 1130 L1

END OF SEARCH HISTORY

Hit List

[First Hit](#) [Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 10 of 33 returned.

☐ 1. Document ID: US 7101977 B2

L8: Entry 1 of 33

File: USPT

Sep 5, 2006

US-PAT-NO: 7101977

DOCUMENT-IDENTIFIER: US 7101977 B2

TITLE: Therapeutic agents comprising pro-apoptotic proteins

DATE-ISSUED: September 5, 2006

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20030086919 A1

May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rosenblum; Michael G.	Houston	TX		US
Liu; Yuying	Houston	TX		US

US-CL-CURRENT: 530/387.1; 435/183

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	--------	-----	-----------	-----

☐ 2. Document ID: US 7091226 B2

L8: Entry 2 of 33

File: USPT

Aug 15, 2006

US-PAT-NO: 7091226

DOCUMENT-IDENTIFIER: US 7091226 B2

TITLE: Cancer treatment with epothilones

DATE-ISSUED: August 15, 2006

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20050165071 A1

July 28, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Reilly; Terence	Basel			CH
Wartmann; Markus	Riehen			CH
Litchman; Manuel	Teaneck	NJ		US
Cohen; Pamela	Tenafly	NJ		US

US-CL-CURRENT: 514/365

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	--------	-----	-----------	-----

☐ 3. Document ID: US 7087636 B2

L8: Entry 3 of 33

File: USPT

Aug 8, 2006

US-PAT-NO: 7087636

DOCUMENT-IDENTIFIER: US 7087636 B2

TITLE: Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function

DATE-ISSUED: August 8, 2006

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20030181728 A1

September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Salvati; Mark E.	Lawrenceville	NJ		US
Balog; James Aaron	Lambertville	NJ		US
Pickering; Dacia A.	Lawrenceville	NJ		US
Zhu; Hong	Lawrenceville	NJ		US

US-CL-CURRENT: 514/412; 548/453

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 4. Document ID: US 7071181 B2

L8: Entry 4 of 33

File: USPT

Jul 4, 2006

US-PAT-NO: 7071181

DOCUMENT-IDENTIFIER: US 7071181 B2

TITLE: Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors

DATE-ISSUED: July 4, 2006

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20040214811 A1

October 28, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Davis; Harry R.	Berkeley Heights	NJ		US
Kosoglou; Teddy	Jamison	PA		US
Picard; Gilles J.	Braine L'Alleud			BE
Ress; Rudyard J.	Flemington	NJ		US
Strony; John T.	Lebanon	NJ		US
Veltri; Enrico P.	Princeton	NJ		US

US-CL-CURRENT: 514/210.02; 514/23, 514/25, 536/17.4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 5. Document ID: US 7056906 B2

L8: Entry 5 of 33

File: USPT

Jun 6, 2006

US-PAT-NO: 7056906

DOCUMENT-IDENTIFIER: US 7056906 B2

TITLE: Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women

DATE-ISSUED: June 6, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20030119796 A1	June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Strony; John T.	Lebanon	NJ		US

US-CL-CURRENT: 514/210.02; 514/170, 514/27, 536/17.4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-----

☐ 6. Document ID: US 7053080 B2

L8: Entry 6 of 33

File: USPT

May 30, 2006

US-PAT-NO: 7053080

DOCUMENT-IDENTIFIER: US 7053080 B2

TITLE: Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors

DATE-ISSUED: May 30, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20030119428 A1	June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Davis; Harry R.	Berkeley Heights	NJ		US
Ress; Rudyard J.	Flemington	NJ		US
Strony; John T.	Lebanon	NJ		US
Veltri; Enrico P.	Princeton	NJ		US

US-CL-CURRENT: 514/210.02; 514/23, 514/25, 514/449, 536/17.4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-----

☐ 7. Document ID: US 7052692 B1

L8: Entry 7 of 33

File: USPT

May 30, 2006

US-PAT-NO: 7052692
DOCUMENT-IDENTIFIER: US 7052692 B1

TITLE: Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus
2-mediated transgene expression

DATE-ISSUED: May 30, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Srivastava; Arun	Indianapolis	IN		US
Qing; Keyun	Indianapolis	IN		US
Wang; Xu-Shan	Carmel	IN		US
Ponnazhagan; Selvarangan	Birmingham	AL		US
Bajpai; Anil	Indianapolis	IN		US

US-CL-CURRENT: 424/135.1; 424/130.1, 424/134.1, 424/141.1, 424/152.1, 424/93.1, 424/93.2,
424/93.6, 435/320.1, 435/325, 435/366, 435/455, 435/456, 435/457, 435/5, 435/6, 435/7.1,
514/2, 514/44, 536/23.1, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences		Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	--	--------	-----	-----------	-----

☐ 8. Document ID: US 7045317 B2

L8: Entry 8 of 33

File: USPT

May 16, 2006

US-PAT-NO: 7045317

DOCUMENT-IDENTIFIER: US 7045317 B2

**** See image for Certificate of Correction ****

TITLE: Bardet-biedl susceptibility gene and uses thereof

DATE-ISSUED: May 16, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20030170645 A1	September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sheffield; Val C.	Iowa City	IA		US
Mykytyn; Kirk	Iowa City	IA		US
Stone; Edwin M.	Iowa City	IA		US

US-CL-CURRENT: 435/69.1; 530/350, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences		Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	--	--------	-----	-----------	-----

☐ 9. Document ID: US 7001911 B2

L8: Entry 9 of 33

File: USPT

Feb 21, 2006

US-PAT-NO: 7001911

DOCUMENT-IDENTIFIER: US 7001911 B2

TITLE: Fused cyclic modulators of nuclear hormone receptor function

DATE-ISSUED: February 21, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20040077606 A1	April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Salvati; Mark E.	Lawrenceville	NJ		US
Balog; James Aaron	Lambertville	NJ		US
Shan; Weifang	Princeton	NJ		US
Giese; So	New Hope	PA		US
Harikrishnan; Lalgudi S.	Princeton	NJ		US

US-CL-CURRENT: 514/292; 544/183, 544/337, 544/348, 546/23, 546/86, 548/453, 548/531, 548/536

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 10. Document ID: US 7001892 B1

L8: Entry 10 of 33

File: USPT

Feb 21, 2006

US-PAT-NO: 7001892

DOCUMENT-IDENTIFIER: US 7001892 B1

TITLE: Pharmaceutical materials and methods for their preparation and use

DATE-ISSUED: February 21, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chmielewski; Jean A.	Lafayette	IN		US
Kahr; Bart E.	Seattle	WA		US
Lewis; Jerry	Carmel	IN		US

US-CL-CURRENT: 514/53; 536/123.13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

L7 and (preservative)

33

Display Format: Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)